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SINTESIS, PENCIRIAN DAN PENILAIAN POTENSI SITOTOKSIK IN 
VITRO KOMPLEKS ARGENTUM(I) MONO, DI, TRI DAN TETRA N-
HETEROSIKLIK KARBENA 
 
ABSTRAK 
Tesis ini memaparkan tentang sintesis, pencirian dan penilaian potensi 
sitotoksik in vitro untuk dua puluh enam kompleks baru mono, di, tri dan tetra NHC-
Ag(I) yang dihasilkan daripada dua puluh enam garam baru mono, bis, tris dan 
tetrakis benzimidazolium. Empat siri garam yang mempunyai terminal N-pergantian 
yang simetrikal telah disediakan. Lapan jenis garam baru bergantian mono 
benzimidazolium yang bersimetri (1-8) telah disintesis menggunakan N-n-alkilasyen 
(n=3-10) yang berperingkat, manakala lapan jenis garam baru bis benzimidazolium 
bergantian yang bersimetri N-alkil (9-16) telah dihasilkan daripada satu sistem 
tetrametilin yang bersilang. Sintesis untuk garam tris dan tetra benzimidazolium 
telah dijalankan menggunakan cadangan dan skema yang direka baru yang 
melibatkan generasi lima baru pelopor garam (17-21), antaranya 3-(2-bromoetil)-1-
bergantian benzimidazolium bromida (benzil/ n-butil/ cyclopentil/ 2-
methylenebenzonitril/ n-decil). Pelopor-pelopor ini telah bertindak balas dengan 
benzimidazol menghasilkan lima generasi baru garam benzimidazolium tris 
bersilang dimetilin (22-26). Tambahan lagi, lima garam benzimidazolium asiklik 
tetra baru telah didapati melalui tindak balas garam pelopor yang pada permulaan 
nya adalah 1,2-bis(benzimidazol-1-ilmetil)benzena yang telah disintesis. Garam 
untuk keempat-empat siri telah ditukar kepada kompleks NHC-Ag(I) masing-masing 
menggunakan kaedah in situ deprotonasi dan pengkompleksan melibatkan Ag2O, 
xxviii 
 
menghasilkan pengasingan 26 kompleks baru NHC-Ag(I) (32-57). Struktur untuk 
semua garam dan kompleks NHC-Ag(I) telah dibuktikan menggunakan satu 
kombinasi spektra (FTIR, 1H, 13C-NMR) dan analisis (CHN) elemental. Kajian 
hablur sinaran-X untuk kompleks (38, 39, 45, 47 and 55) telah menunjukkan motif 
pengikatan untuk kompleks mono, di dan tetra NHC-Ag(I). Potensi antikanser in 
vitro untuk kesemua empat siri garam dan kompleks NHC-Ag(I) masing-masing 
telah diperiksa terlebih dahulu melawan bahagian sel kanser kolon (HCT116) 
manusia. Terdapat peningkatan dalam aktiviti antikanser apabila peningkatan 
panjang rantai penggantian dalam kes siri mono dan di, yang mana siri di telah 
dijumpai lebih aktif berbanding siri mono. Siri tri dan tetra menunjukkan aktiviti 
yang dipilih terhadap bahagian sel kanser kolon manusia, dan kemudiannya telah 
diperiksa melawan bahagian sel kanser payudara (MCF-7) dan kanser serviks 
(HeLa), di mana kesemua kompleks telah menunjukkan aktiviti antikanser. Dalam 
semua siri, kompleks NHC-Ag(I) telah dijumpai lebih aktif daripada proligan 
masing-masing. Pengkajian tentang kesan penggantian terhadap potensi antikanser 
melawan bahagian kanser sel yang dipilih telah membuktikan bahawa garam dan 
kompleks yang mempunyai rantai n-alkil yang paling panjang (n-dekil) daripada 
setiap siri yang dikaji adalah paling aktif. Aktiviti ini mungkin disebabkan oleh 
peningkatan lipofilisiti untuk penggantian n-dekil. Dalam untuk mendapatkan lebih 
pencerahan tentang mekanisma tindakan kompleks-kompleks baru tetra NHC-Ag(I) 
yang direka dan garam masing, kompleks 57 and garam 31-nya telah dipilih untuk 
pengkajian seteruskan dalam asas indeks pemilihan. Sebatian yang dipilih telah 
dikaji untuk mekanisma perencatan migrasi sel dan perencatan pembentukan koloni. 
Kompleks dan garamnya yang dipilih telah dijumpai untuk menunjukkan potensi 
antikanser dengan perencatan pembentukan koloni dan migrasi sel kanser.  
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SYNTHESIS, CHARACTERIZATION AND IN VITRO EVALUATION OF 
CYTOTOXIC POTENTIAL OF MONO, DI, TRI AND TETRA                         
N-HETEROCYCLIC CARBENE SILVER(I) COMPLEXES 
 
ABSTRACT 
This thesis presents the synthesis, characterization and in vitro evaluation of 
cytotoxic potential of twenty six new mono-, di-, tri- and tetra-NHC-Ag(I) 
complexes derived from twenty six new mono-, bis-, tris- and tetrakis- 
benzimidazolium salts. The four series of salts with symmetrical terminal N-
substitution were prepared. The eight new symmetrically substituted mono 
benzimidazolium salts (1-8) were prepared by stepwise N-n-alkylation (n=3-10), 
while the eight new symmetrically n-alkyl substituted bis benzimidazolium salts (9-
16) were derived from tetramethylene linked system. The synthesis of tris and 
tetrakis benzimidazolium salts was carried out by newly designed schemes that 
involved the generation of the five new precursor salts (17-21), namely 3-(2-
bromoethyl)-1-substituted benzimidazolium bromide (benzyl/ n-butyl/ cyclopentyl/ 
2-methylenebenzonitrile/ n-decyl). These precursors were reacted with 
benzimidazole thus resulting in the generation of five new dimethylene linked tris 
benzimidazolium salts (22-26). Another five new acyclic tetrakis benzimidazolium 
salts (27-31) were obtained by reacting the precursor salts (17-21) with the initially 
synthesized 1,2-bis(benzimidazol-1-ylmethyl)benzene. The salts of all the four series 
were converted to their respective NHC-Ag(I) complexes using the in situ 
deprotonation and complexation method involving Ag2O, thus resulting in the 
formation of twenty six new NHC-Ag(I) complexes (32-57). The structures of all the 
xxx 
 
salts and NHC-Ag(I) complexes were established by a combination of spectral 
(FTIR, 1H, 13C-NMR) and elemental (CHN) analysis, while the X-ray crystal studies 
of complexes (38, 39, 45, 47 and 55) revealed the bonding motifs of mono, di and 
tetra NHC-Ag(I) complexes. The in vitro cytotoxic potential of all the four series of 
salts and their respective NHC-Ag(I) complexes was preliminary tested against 
human colon cancer cell lines (HCT116). There was an increase in cytotoxic 
activities with increase in the alkyl chain length of substituents in the mono- and di-
NHC series, while the di-NHC series was found to be more active as compared to the 
mono-NHC series. On the other hand tri- and tetra-NHC series showed selective 
activities on human colon cancer cell line and were further tested against breast 
cancer (MCF-7) and cervical cancer cell line (HeLa) of which all the complexes in 
both series displayed anticancer activities. In all the above mentioned series, the 
NHC-Ag(I) complexes were found to be more active than their respective 
proligands. The investigation of the effect of substitutions on cytotoxic potential on 
the selected cancer cell lines showed that the salts and complexes having the longest 
n-alkyl chain (n-decyl) in each series were the most potent. That may be attributed to 
the increased lipophilicity of the n-decyl substituent. In order to gain preliminary 
insights into the mode of cytotoxic activity of the newly designed tetra NHC-Ag(I) 
complexes and their respective salts, complex 57 and its respective salt 31, were 
selected for investigation. The selected complex and its respective salt were found to 
display cytotoxic potential by inhibiting the colony formation and migration of 
cancer cells. 
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                                CHAPTER 1 
INTRODUCTION 
 
1.1 The Carbenes 
Carbenes are uncharged species comprising a divalent carbon atom with six 
valence electrons. Depending on the geometry at the carbene carbon atom, they can 
either be sp2 or sp hybridized. The carbene carbon atom with a linear geometry is sp 
hybridized with two energetically degenerated p orbitals whereas the sp2 hybridized 
carbon atom having a σ and a pπ orbital adopts a bent geometry. The carbon atom in 
most carbenes is sp2 hybridized state as it is energetically more stable as compared to 
those with sp hybridized carbon (Hahn & Jahnke 2008). 
The sp2 hybridized carbenes can be further distinguished as either singlet or 
triplet carbenes depending on the multiplicity of the ground state which is 
determined by the relative energies of the σ and pπ orbitals. If the energy difference 
between the two orbitals is large, then the two nonbonding electrons will occupy the 
σ orbital with an antiparallel spin orientation leading to the singlet ground state. 
Conversely, if there is less energy difference, the nonbonding electrons will occupy 
the independent σ and pπ orbitals with a parallel spin orientation resulting in a triplet 
ground state (Figure 1.1). The ground state multiplicity of carbenes determines their 
properties and reactivity (Schuster, 1987). 
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Figure 1.1: Representation of spin multiplicities of sp2 hybridized carbenes. 
It is generally thought that the substituents at the carbene carbon atom control 
the multiplicity of the ground state owing to their steric and electronic effects. In case 
of inductive effect, σ- electron withdrawing substituents favour the singlet ground 
state as they lower the energy of the nonbonding σ orbital through their negative 
inductive effect. Alternatively, σ-electron donating substituents favour the triplet 
ground state by decreasing the energy gap between the σ and pπ orbitals. In addition 
to the inductive effects, the mesomeric effect of the substituent also plays a vital role 
in determining the multiplicity of the carbene. The π-electron donating substituents 
raises only the energy of the pπ orbital, increasing the energy gap of σ and pπ orbitals 
which also results in a stable singlet ground state. On the other hand, the π-electron 
accepting substituents lend the carbene in a singlet ground state with almost linear 
geometry (Schoeller, 1980).   
The efforts for the synthesis and isolation of free carbenes started as early as 
1835 by J. B. Dumas who attempted to dehydrate methanol to get methylene. The 
first firm structural evidence for the formation of dichloro carbene was reported by 
Doering (von E. Doering & Hoffmann, 1954) as an intermediate in cyclopropanation 
reaction.  At that time, carbenes were considered as highly reactive, short lived 
intermediates in organic transformations. Soon after that, the concept of double bond 
between transition metals and carbon was introduced by Fischer with the first 
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recognized heteroatom stabilized carbene complex in organometallic chemistry 
(Scheme 1.1) (Fischer & Maasbol, 1964). Afterwards, a number of tantalum carbene 
complexes were reported by Schrock (Scheme 1.2) (Schrock, 1974). Around the 
same time Wanzlick introduced the concept of N-heterocyclic carbenes and later in 
1968, metal complexes with N-heterocyclic carbene ligands were reported. After the 
discovery of these metal carbene complexes, the exploration of their chemistry 
began. 
 
Scheme 1.1: Synthesis of the first Fischer carbene complex. 
 
Scheme 1.2: Synthesis of the first Schrock carbene complex. 
 
1.2 Classification of carbenes 
During the development of metal-carbene complexes, three different patterns 
of reactivity and bonding emerged resulting in their classification into different types 
as described below. 
1.2.1 Fischer carbenes 
Fischer carbenes are singlet carbenes with two nonbonding electrons in the σ 
orbital having a vacant pπ orbital and at least one good π-donor substituent. The 
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metal-carbene chemical bond is formed by the donation of the lone pair from the σ 
orbital of the carbene to an empty dσ orbital of that metal. The empty pπ orbital of 
carbene is stabilized by π-donation from the substituent as well as π-back-bonding 
from the filled dπ orbital of the metal. As the late transition metals (low oxidation 
state) have stabilized dπ orbitals and are good π-donors, they tend to stabilize the 
Fischer type carbenes. This bonding pattern leaves the carbon electrophilic because 
the direct carbene to metal donation is only partly compensated by metal to carbene 
π-back-donation (Figure 1.2). 
 
 
Figure 1.2: Carbene to metal bonding in Fischer carbene. 
1.2.2 Schrock carbenes 
Schrock carbenes are triplet carbenes with both σ and pπ orbitals singly 
occupied. These carbenes must have substituents that are not π-donors, such as alkyl 
groups, in order to inhibit the repulsions of electrons. In this case, the carbene forms 
two covalent bonds with the metal each polarized towards the carbon making it 
nucleophilic (Figure 1.3). Schrock carbenes form complexes with early transition 
metals (high oxidation state).  
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Figure 1.3: Carbene to metal bonding in Schrock carbene. 
1.2.3 N-heterocyclic carbenes 
N-heterocyclic carbenes (NHCs) are singlet carbenes and have two adjacent 
π-donating nitrogen atoms. The NHCs bond to metals through the σ-donation of the 
carbene lone pair. The empty pπ orbital of the carbene is strongly stabilized by π-
donation from the nitrogen atoms (Figure 1.4). This electron donation gives 
nucleophilic character to the NHCs and makes them excellent σ-donors to transition 
metals both in low and high oxidation states as well as to main group metals. 
Contrary to the Fischer and Schrock carbenes, the NHCs are stable, capable of 
independent existence and can be readily prepared. 
 
 
Figure 1.4: Carbene to metal bonding in N-heterocyclic carbene. 
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1.3 Emergence of N-heterocyclic carbenes  
H.W. Wanzlick was the pioneer bringing NHC into focus in 1960. He 
hypothesized that the carbenes could be stabilized by the presence of amino 
substituents in N-heterocyclic systems based on the fact that the delocalization of six 
π-electrons in such systems would stabilize the carbene. He therefore tried to prepare 
and isolate 1,3-diphenylimidazolidin-2-ylidene by thermal elimination of chloroform, 
instead of NHC, only its dimer, the enetetraamine was obtained and consequently the 
postulated equilibrium between the monomer and the dimer could not be proven.  
(Scheme 1.3) (Wanzlick, 1962; Wanzlick & Kleiner, 1961; Wanzlick & Schikora, 
1960). Furthermore, he attempted to prepare free NHC by the deprotonation of 
tetraphenyimidazolium perchlorate with potassium tert-butoxide, although the 
expected free NHC could not be isolated, yet its intermediate formation was 
demonstrated (Schonherr & Wanzlick, 1970).  
 
 
Scheme 1.3: Attempted synthesis of free carbene by Wanzlick. 
 In 1991, Arduengo and co-workers reported the successful synthesis and 
isolation of the first crystalline free carbene that was stable in the absence of oxygen 
and moisture. The stable 1,3-di-adamantyl-imidazol-2-ylidene was obtained by the 
deprotonation of 1,3-di-adamantyl-imidazolium chloride using one equivalent of 
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sodium hydride with a catalytic amount of DMSO anion or potassium tertiary 
butoxide in THF at room temperature (Arduengo III et al., 1991) (Scheme 1.4).  
 
 
Scheme 1.4: Synthesis of the first stable free carbene by Arduengo.  
The resulting carbene was found to be thermally stable with a melting point 
of 240-241°C without decomposition and it was also fully characterized and 
elucidated crystallographically. The isolation of this stable carbene initially led to the 
assumption that its stability is due to the steric bulk around it but further work by 
Arduengo negated this view where he successfuly isolated a carbene with only 
methyl substituents on the heterocycle (Figure 1.5(a)) along with  three more stable 
NHCs having different substitution patterns (Arduengo III, Dias, Harlow, et al., 
1992) [Figure 1.5(b, c, d)]. The aromaticity of the NHC system which was  initially 
considered as one of the necessary factors for the stability of free NHC was proven 
not to be of prime importance by the synthesis of stable imidazolin-2-ylidene (Figure 
1.5(e))  with non aromatic heterocycle (Arduengo III et al., 1995). All these NHCs 
were synthesized under the same experimental conditions. Later on, Arduengo and 
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co-workers were also successful in synthesizing free 1,3,4,5-tetraphenylimidazol-2-
ylidene (Figure 1.5(f)) by the modification of Wanzlick’s experimental procedure.  
The avenue opened up by Arduengo to the isolation of free carbene had led 
others to synthesize and isolate stable carbenes by applying different methods. Kuhn 
and co-worker reported the  synthesis of alkyl substituted imidazol-2-ylidene by the 
reduction of imidazole-2-(3H)-thione using potassium in boiling THF (Kuhn & 
Kratz, 1993). The first commercially available carbene derived from a triazole (1,2,4-
triazol-5-ylidene) was synthesized by Enders and co-workers (Enders et al., 1995). 
Herrmann and co-workers reported a number of functionalized imidazoline-2-
ylidenes by introducing a new synthetic strategy involving the use of liquid ammonia 
in aprotic organic solvent along with a base (Herrmann et al., 1996). This new 
method of carbene generation offers advantage over other reported methods in term 
of reaction time as carbenes can be generated in few minutes and in high yield. The 
use of liquid ammonia serves to increase the solubility of imidazolium salts in 
organic solvents and also increases the acidity of C-2 protons through hydrogen 
bonding. Danopoulos and co-workers reported the 2,6-bis(arylimidazol-2-
ylidene)pyridine which was the first stable pincer based bis carbene (Danopoulos et 
al., 2002). 
In addition to the cyclic amino carbenes, Alders and co-workers had 
successfully generated an acyclic amino carbene, bis(diisopropylamino)carbene thus 
showing that the amino substituent plays a vital role in the stabilization of carbenes 
without the need of a cyclic structure (Alder et al., 1996). In the studies focussing on 
NHC, apart from the five membered N-heterocyclic carbenes, a stable six-membered 
NHC, 1,3-diisopropyl-3,4,5,6-tetrahydropyrimid-2-ylidene was also reported (Alder 
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et al., 1999). The carbenes of the class imidazol-2-ylidene still form the major type of 
stable NHCs.  
 
 
Figure 1.5: Structures of reported stable carbenes (a-f) by Arduengo.   
From the above discussed literature, one can conclude that N-heterocyclic 
carbenes can be of different classes depending on the N-heterocyclic system, from 
which they are generated and therefore named accordingly. The systematical names 
of the parent heterocyclic compounds are given a suffix that is determined by the 
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kind of heterocyclic system, followed by the addendum –ylidene. The term “ylidene” 
refers to a compound in which two hydrogens are replaced by a pair of electrons 
hereby referring to the carbene and is mentioned along with the position of the 
carbene carbon in the N-heterocyclic system. Figure 1.6 depicts some of the most 
common classes of N-heterocyclic carbenes. 
 
 
Figure 1.6: Structures of some of the most commonly applied classes of NHCs. 
1.3.1 N-heterocyclic carbene complexes 
NHCs as strong nucleophiles and excellent σ-donors, form adducts with 
virtually all the elements of the periodic table. The NHC complexes with transition 
metals were brought into focus even before the synthesis and isolation of the first 
reported free N-heterocyclic carbene, while with main group elements, the 
complexes began to be explored soon after the discovery of free NHC. 
The most commonly used methods for the synthesis of NHC complexes are 
as follows:  
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1.3.1(a) In situ deprotonation of azolium salts 
This method is based on the in situ deprotonation of the carbene precursor 
(azolium salt) which is achieved either by the use of metal source of sufficient 
basicity to deprotonate the azolium salts such as metal hydrides, alkoxides and 
acetates or by the addition of external bases such as potassium tert-butoxide, sodium 
hydride, sodium hydroxide, triethylamine to the metal source (Weskamp et al., 
2000). The in situ deprotonation is the first known synthetic route for the formation 
of NHC transition metal complexes as demonstrated independently by Wanzlick and 
Öfele (Ofele, 1968; Wanzlick & Schonherr, 1968) [Scheme 1.5 (a,b)]. This method 
has also been reported for the synthesis of NHC complexes with rare earth metals 
(Clark et al., 2014; Gu et al., 2015; Lv & Cui, 2008; Wang et al., 2006). Most of the 
literature related to NHC transition metal complexes focuses on this method as it 
offers the advantage that the free carbene does not have to be isolated. 
 
 
 
Scheme 1.5: Synthesis of the first NHC transition metal complexes by (a) Wanzlick 
and (b) Öfele.  
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1.3.1(b) Free carbene route 
In this method, first the free NHC is generated by the deprotonation of 
azolium salts using strong bases such as KH, NaH or KOtBu and the subsequent 
reaction of the free carbene with appropriate metal/element source yields the NHC 
complex. This is a useful method for those azolium salts that could generate free 
NHCs. Arduengo and coworkers, soon after the isolation of the first free stable NHC,  
reported the synthesis of a variety NHC transition metal complexes of Ag, Cu, Ni, Pt 
and Zn by such method (Arduengo et al., 1993; Arduengo et al., 1994) and it is still 
in use for the synthesis of different transition metal complexes (Alcarazo, 2005; 
Tapu, 2016). The rare earth metals have also been reported to form stable adducts 
with NHCs in high yields by utilizing this method (Herrmann et al., 1994); 
(Arduengo et al., 1994; Ferrence et al., 2006; Herrmann et al., 1997; Mehdoui et al., 
2005; Schumann et al., 2007; Schumann et al., 1994a, 1994b). 
The free carbene route is most commonly used for the synthesis of NHC 
complexes with main group metals and elements. The derivatives of alkali and 
alkaline earth metals have been reported to form stable monomeric as well as dimeric 
adducts with NHCs (Alder et al., 1999; Arduengo et al., 1998; Maddock et al., 2015). 
NHCs strongly coordinate to a multitude of different p-block species, leading to 
adducts with a variety of different structures. For example, among group 13 the first 
NHC-alane adduct, imidazol-2-ylidene-AlH3 was reported by Arduengo (Arduengo 
et al., 1992) (Scheme 1.6). Imidazol-2-ylidenes form stable monomeric adducts with 
B, Al, Ga derivatives which have been isolated as trihydrides, trimethyl and 
trichlorides (Abernethy et al., 2000; Kuhn et al., 1993; Marion et al., 2007). From the 
group 14 species, 1,3-mesityl-imidazolin-2-ylidenes, when reacted with methyl 
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iodide, form stable olefin along with the formation of imidazolinium salt (Arduengo, 
Davidson, et al., 1997). The imidazol-2-ylidenes can form stable tetravalent, 
pentavalent and hexavalent adducts with silicon and tin derivatives (Filippou et al., 
2013; Jones et al.; Kuhn et al., 1995). The  cyclic oligomers of phosphorous and 
arsenic among group 15 species form stable adducts with 1,3-dimesitylimidazol-2-
ylidene (Arduengo, Calabrese, et al., 1997).The chalcogens (O, S, Se, Te) with 
imidazol-2-ylidenes have been reported to give stable imidazolium chalcogenides 
(Enders et al., 1995; Huffer et al., 2013). Among halogens, stable adducts with iodine 
and chlorine have been obtained by the reaction of imidazol-2-ylidenes with iodine 
and dichloroethane, respectively (Kuhn et al., 1998; Kuhn et al., 1993). 
 
 
Scheme 1.6: Synthesis of NHC alane adduct. 
1.3.1(c) Ligand transfer reactions 
It involves the transfer of NHC ligand from one labile metal to another. Liu 
and co-workers have reported the successful transfer of NHC ligand from the NHC 
complexes of W(0), Cr(0), Mo(0) to Pd(II), Pt(II), Rh(I) and Au(I) (Liu, 1998) 
(Scheme 1.7). The use of NHC-Ag(I) complexes as NHC transfer agents was 
introduced by Wang and Lin and is found promising in getting a variety of other 
transition metal complexes (Wang & Lin, 1998). Transmetallation involving the use 
of NHC-Ag(I) is discussed in detail under applications of NHC-Ag(I) complexes. 
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Apart from NHC-Ag(I), the use of NHC-Hg(II) complexes as NHC-transfer agents 
have also been reported to give successful transmetallation results (Baker et al., 
2009; Lin & Vasam, 2007; Meyer et al., 2012). The NHC-Cu(I) complexes have also 
been reported to readily transfer the NHC ligand to Pd(II) and Au(I) (Furst, 2010) as 
well as Rh(I) and Ir(I) (Bidal, 2016). Apart from transition metal complexes, NHC-Li 
complexes have also been reported as effective carbene transfer agents (Arnold et al., 
2003; Arnold et al., 2004; Liddle & Arnold, 2005). A variety of transition metal 
complexes such as Au(I), Cu(I), Cu(II), Ni(II), Pd(II), Pt(II), Rh(I), Rh(III), Ir(I), 
Ir(III), Ru(II), Ru(III) and Ru(IV) can be obtained by this method.  
 
 
Scheme 1.7: Ligand transfer reaction from W(0) to Au(I).  
1.3.1(d) Cleavage of enetetraamines 
This method was introduced by Lappert and coworkers (Cardin, 1971). It 
involves the cleavage of electron rich enetetraamines (tetraaminoethylenes) into 
carbene monomers in the presence of coordinatively unsaturated electrophilic metal 
sources, resulting in the coordination of carbene with the metal center. This method 
has been successfully used for the synthesis of mono, bis, tris and tetrakis carbene 
complexes of various metals such as Cr, Mo, W, Mn, Fe, Ru, Os, Co, Rh, Ir, Ni, Pd, 
Pt, Au, Hg and Sn in different oxidation states (Cetinkaya et al., 1994; Hahn et al., 
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2001; Hitchcock et al., 1978; Karaca et al., 2015; Lappert, 2005; Lappert & Pye, 
1977) (Scheme 1.8). 
 
Scheme 1.8: Synthesis of NHC transition metal complex by the cleavage of electron 
rich enetetraamines. 
 
1.4 N-heterocyclic carbene silver(I) complexes 
Among the NHC-transition metal complexes, NHC-Ag(I) complexes have 
gained much focus due to their simpler synthetic strategies and stability, diverse 
structural architectures and various promising applications. All these aspects of 
NHC-Ag(I) complexes are discussed below.  
1.4.1 Synthesis of N-heterocyclic carbene silver(I) complexes 
NHC-Ag(I) complexes can be successfully synthesized by the following two 
methods: 
1.4.1(a) The free carbene method 
The first NHC-Ag(I) complex reported by Arduengo was obtained by the 
direct reaction of a preformed 1,3-dimesitylimidazol-2-ylidene with silver triflate, 
thus resulting in the formation of a bis(carbene) Ag(I) adduct  (Arduengo et al., 
1993) (Scheme 1.9). NHC-Ag(I) complexes derived from five, six and seven 
membered free NHCs have also been reported (Iglesias, 2008). As this method 
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requires the initial generation of free carbene, it is limited to those azolium salts that 
can generate stable carbenes. 
 
Scheme 1.9: Synthesis of the first NHC-Ag(I) complex by Arduengo using free 
carbene. 
1.4.1(b) The in situ deprotonation method 
The in situ deprotonation of azolium salt and complexation of resulting 
carbene with Ag(I) can be accomplished either by the use of a silver base, Ag2O or 
the basic silver salts like AgOAc and Ag2CO3 (Scheme 1.10).  
The first introduced in situ deprotonation method involved the use of silver 
acetate as a silver base to deprotonate 1,2,4-trisubstituted triazolium salt, resulting in 
the formation of a polymeric NHC-Ag(I) complex (Guerret et al., 1997). This 
method   has now been used for the preparation of NHC-Ag(I) acetate complexes 
(Hindi et al., 2008; Patil et al., 2011). In 1998, Wang and Lin introduced a new 
method which involved the use of silver oxide (Wang & Lin, 1998). This method has 
gained much popularity and is most commonly used for the preparation of NHC-
Ag(I) complexes. It involves the reaction of azolium salt with Ag2O, resulting in 
deprotonation of C2 carbon (precarbenic carbon) and complexation of the resulting 
carbene with Ag(I) at the same time. This reaction requires no external base and 
special reaction conditions like inert atmosphere and for the most part, it is carried 
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out at room temperature with the exception of azolium salts with steric bulk around 
C2 carbon that needs refluxing (Tulloch et al., 2000). For this method, a number of 
different solvents like dichloromethane, dichloroethane, acetone, methanol, 
acetonitrile, DMSO, DMF, water and solvent mixtures can also be used. The 
resulting NHC-Ag(I) complexes are stable, high in yield and have an added 
advantage of being excellent carbene transfer agents to obtain other transition metal 
complexes (Lin & Vasam, 2007; Lu et al., 2012).  
 
Scheme 1.10: A general representation of in situ deprotonation methods for the 
synthesis of imidazolium/benzimidazolium derived NHC-Ag(I) complexes. 
Another method of in situ deprotonation and complexation which involves 
the use of silver carbonate was reported in 2000 (Tulloch et al., 2000). This method 
offers longer reaction times and is of limited use, therefore the Ag2O route remaines 
the preferred one. Most of the literature known NHC-Ag(I) complexes have been 
reported to be synthesized utilizing Ag2O (Haque et al., 2013; Karataş et al., 2016; 
Samanta et al., 2015; Segarra et al., 2014)  
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1.4.2 Classification of N-heterocyclic carbene silver(I) complexes 
The NHC metal complexes can be classified taking into account either the 
number of NHC unit per ligand molecule or by considering the number of metal 
centers per complex. However, the review articles dealing with the structural 
diversity of NHC metal complexes classify them mostly on the basis of NHC units 
per ligand (Garrison & Youngs, 2005; Poyatos et al., 2009). The NHC metal 
complexes are broadly classified into two main categories namely the mono-NHC 
and the poly-NHC, the latter can further be subdivided into different types. 
 The present classification is based on the number of carbene centres per 
ligand, of which the NHC-Ag(I) complexes can be of the following types; 
1.4.2(a) Mono NHC-Ag(I) complexes 
The mono-NHC (monodentate) ligands have one NHC unit per ligand 
molecule in the complex. Different bonding motifs of mono NHC-Ag(I) complexes 
can be obtained depending on whether the anion is noncoordinating or coordinating. 
The mono NHC-Ag(I) complexes with noncoordinating anions exist as 
dimeric complexes with one Ag(I) ion bridging two NHC ligands giving rise to 
monometal diligand arrangement (Asekunowo & Haque, 2014) [Figure 1.7(a)]. 
Whereas with the coordinating anion, mainly halides, different structural variations 
are possible. The monomeric complexes with one Ag(I) ion coordinating to a carbene 
and an anion (Ramnial et al., 2003) [Figure 1.7(b)];  the mono NHC-Ag(I) 
complexes with bridging halides (Tulloch et al., 2000) [Figure 1.7(c)]; and the 
complexes forming staircases (Chen & Liu, 2003) (Figure 1.7(d)). 
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Figure 1.7: Structural variations of mono NHC-Ag(I) complexes.  
1.4.2(b) Di NHC-Ag(I) complexes 
The di-NHC (bidentate) ligands have a pair of NHC moieties connected via a 
bridging linker such as phenylene (Alcalde et al., 2007) (Haque et al., 2013), 
lutidinyl (Brown et al., 2009) (Haque et al., 2014), ether chain (Liu et al., 2007; 
Nielsen et al., 2003) or alkyl chain (Gil-Rubio et al., 2013) (Haque et al., 2013).  
Depending on the flexibility and the size of the bridging linker, NHC-Ag(I) 
complexes can have four structural variations: the monometal monoligand complex 
[Figure 1.8(a)]; the bidentate monoligand and dimetal complexes [Figure 1.8(b)]; the 
dimetal diligand complex [Figure 1.8(c)] and the di-NHC-Ag(I) complexes derived 
from imidazolium linked cyclophanes (Baker et al., 2004) [Figure 1.8(d)]. 
 
